New Delhi: Amidst the havoc of the corona epidemic, all eyes are on the vaccine. Meanwhile, the relief news is that the Serum Institute, a vaccine trial of Oxford and AstraZeneca in India, has overcome the major challenge of clinical trial of the third phase of corona virus vaccine.
According to media reports, the Serum Institute of India and ICMR have announced that the enrolment client of the third phase of the clinical trial for Covishield in India has been completed. As an agency, ICMR and Serum Institute are also working together for the clinical development of The Covovac (COVOVAX, Novavax). The Covowax (COVOVAX) has been created by the Us Novavx and the serum institute is working to advance it.
Earlier, the chief executive officer of the Pune-based country's largest drug manufacturer Serum Institute of India, Adar Puravala, had said that the corona vaccine could come into the market in the country by January 2021. At the same time, if the regulatory bodies are approved at the moment, we can expect that the vaccine will be available in India by January next year", said Adar Puravala.
Also Read:
Health Ministry report on COVID 19 cases in Maharashtra
Health Ministry report on COVID 19 cases in Maharashtra
Google announces account storage policy changes, w.e.f June 1, 2021
4 ministers of Mamata government absent in cabinet meeting